Novartis AG (CHIX:NOVNz)
CHF 87.96 -0.78 (-0.88%) Market Cap: 177.46 Bil Enterprise Value: 193.40 Bil PE Ratio: 11.84 PB Ratio: 4.80 GF Score: 56/100

Novartis AG to Discuss Ofatumumab (OMB157) ECTRIMS Data Investor Call Transcript

Sep 16, 2019 / 02:00PM GMT
Operator

Good morning, and good afternoon, and welcome to the Novartis Investor Call. (Operator Instructions) And the conference is being recorded. (Operator Instructions) With that, I would like to hand over to Samir Shah, Global Head, Investor Relations. Please go ahead, sir.

Samir Shah
Novartis AG - Global Head of IR

Thank you very much, and good morning, and good afternoon, everybody. And thank you for taking the time to join us today as we go through the ECTRIMS data, which was presented last Friday. With myself in the room, we have Marie-France Tschudin. She is the -- as you know, she is the Head of Pharmaceuticals Division within Novartis. We also have Danny Bar-Zohar, who is the Global Development and Analytics Head; and Paul Spittle, who's the Global Commercial Head for Pharmaceuticals Division.

Before we actually start, just a couple of points to mention. The slides for this investor call are available on our website. And I'll also like to read you the safe harbor statement. The information presented today contains forward-looking statements that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot